

FDA updates MDR program in an effort to increase transparency

By **Adrienne R. Lenz, Hyman, Phelps & McNamara***

JULY 9, 2019

FDA recently announced new changes it is making to the Medical Device Reporting (MDR) program as part of its ongoing efforts to increase transparency on device performance, and detection of device-related safety concerns.

FDA is formally discontinuing the Alternative Summary Reporting (ASR) Program, which permitted certain device manufacturers to file quarterly reports rather than individual reports. All data submitted under the program are available on the MDR Data Files web page.

The ASR data is available only in compressed files containing data for one year.

FDA is formally discontinuing the Alternative Summary Reporting Program, which permitted certain device manufacturers to file quarterly reports rather than individual reports.

Starting in 2017, the ASR Program also required manufacturers to submit a “companion” medical device report for visibility through the Manufacturer and User Facility Device Experience (MAUDE) database so the most recent files are searchable. For the years 1999 to 2016, the data are available, but not easy to navigate.

Files from CDRH’s Device Experience Network (DEN) also are available on the MDR Data Files page. These include files from the database that pre-dates the MAUDE database.

Like the ASR data, DEN data are available in compressed, downloadable files containing data by year, but the DEN files also can be searched by product description, product code, manufacturer and report type.

FDA also provided an update on its plans to make the MAUDE database more user friendly and for active surveillance using the National Evaluation System for health Technology (NEST).

While improving the user interface for MAUDE will be helpful, the MDR system is a passive system and has limitations in its use for identifying emerging signals to improve patient safety.

Therefore, FDA claims it is moving to an active surveillance system, leveraging Unique Device Identifiers (UDI) and NEST. Both the MAUDE updates and NEST received funding for development in FY2019 so we look forward to seeing progress in the near future.

This article first appeared in the July 9, 2019, edition of Westlaw Journal Medical Devices.

* © 2019 Adrienne R. Lenz, Hyman, Phelps & McNamara

ABOUT THE AUTHOR



Adrienne R. Lenz, a senior medical device regulation expert at **Hyman, Phelps & McNamara** in Washington, provides consulting to medical device and combination product manufacturers. She assists clients with a wide range of pre- and post-market regulatory topics including developing regulatory strategy, preparing regulatory submissions, drafting regulatory policies and procedures, reviewing advertising and promotional materials, and addressing enforcement matters. She can be reached at alenz@hpm.com. This article was first published June 25, 2019, on the firm’s FDA Law Blog, www.fdadblog.net. Republished with permission.

Thomson Reuters develops and delivers intelligent information and solutions for professionals, connecting and empowering global markets. We enable professionals to make the decisions that matter most, all powered by the world’s most trusted news organization.

This publication was created to provide you with accurate and authoritative information concerning the subject matter covered, however it may not necessarily have been prepared by persons licensed to practice law in a particular jurisdiction. The publisher is not engaged in rendering legal or other professional advice, and this publication is not a substitute for the advice of an attorney. If you require legal or other expert advice, you should seek the services of a competent attorney or other professional. For subscription information, please visit legalsolutions.thomsonreuters.com.

Thomson Reuters is a commercial publisher of content that is general and educational in nature, may not reflect all recent legal developments and may not apply to the specific facts and circumstances of individual transactions and cases. Users should consult with qualified legal counsel before acting on any information published by Thomson Reuters online or in print. Thomson Reuters, its affiliates and their editorial staff are not a law firm, do not represent or advise clients in any matter and are not bound by the professional responsibilities and duties of a legal practitioner. Nothing in this publication should be construed as legal advice or creating an attorney-client relationship. The views expressed in this publication by any contributor are not necessarily those of the publisher.